Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

In Partnership With:

Partner | Cancer Centers | <b>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</b>

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Jessica Hergert.

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Amgen, we had the pleasure of speaking with Benjamin P. Levy, MD, an associate professor of oncology and the clinical director of Medical Oncology at Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, to discuss KRAS-targeted treatment strategies in advanced non–small cell lung cancer (NSCLC).

For the past 30 years, KRAS was believed to be an undruggable target, which has made the emergence of KRAS G12C inhibitors all the more exciting, according to Levy.

The compound that has gained the most notoriety because of its unprecedented activity is AMG 510, said Levy. AMG 510 is a first-in-class investigational agent that selectively and irreversibly targets the KRAS G12C protein.

In September 2019, the FDA granted a fast track designation to the investigational KRAS inhibitor for the treatment of patients with KRAS G12C–mutated NSCLC who have received prior treatment.

The designation was based on updated phase 1 data for a subset of 34 patients with NSCLC, 23 of whom were evaluable for efficacy. Thirteen of the evaluable patients received the target dose of 960 mg once daily. Seven of these patients, or 54%, achieved a partial response at 1 or more time points and 6, or 46%, achieved stable disease; this translated to a disease control rate of 100%.

In our exclusive interview, Dr. Levy discussed the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.